Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose ...

86% Response Rate in Gout Patients After Eight Days of Treatment SAN DIEGO--(BUSINESS WIRE)--Jun. 11, 2009-- Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced positive interim results from an ...

Every investor in Ardea Resources Limited (ASX:ARL) should be aware of the most powerful shareholder groups. We can see that individual investors own the lion's share in the company with 59% ownership ...

Ardea has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issued in the private placement. This press release shall not constitute an offer to ...

Badly in need of new drugs, AstraZeneca has agreed to buy San Diego’s Ardea Biosciences for $1.26 billion to gain access to a promising therapy that fights gout. The deal is the largest local ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Ardea Resources ( ...

Ardea Resources has hit a major milestone in the development of its Goongarrie Hub nickel-cobalt project in Western Australia after executing a binding agreement with a giant Japanese consortium. It ...

Ardea Resources and Brightstar Resources have agreed to a tenement swap as the former looks to expand its Kalgoorlie nickel project Goongarrie Hub, while the latter builds its Menzies gold-lithium ...

The latest update is out from Ardea Resources ( (AU:ARL)). Ardea Resources Limited has announced the issuance of 3,000,000 unquoted options, each convertible at $1.05, with a maturity date set for ...

Ardea Resources has locked in up to a whopping $1 billion in financing support from two government-backed agencies to develop its globally significant Goongarrie nickel hub outside Kalgoorlie in ...

Anglo-Swedish drug company AstraZeneca PLC is buying Ardea Biosciences, Inc., in a deal which values the U.S. biotech company at $1.26 billion. AstraZeneca said Monday that it had agreed the takeover ...